CO6260083A2 - Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentos - Google Patents
Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentosInfo
- Publication number
- CO6260083A2 CO6260083A2 CO10095026A CO10095026A CO6260083A2 CO 6260083 A2 CO6260083 A2 CO 6260083A2 CO 10095026 A CO10095026 A CO 10095026A CO 10095026 A CO10095026 A CO 10095026A CO 6260083 A2 CO6260083 A2 CO 6260083A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- alkylene
- independently
- mono
- Prior art date
Links
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 title 1
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 title 1
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un compuesto de la fórmula Iy/o cualquier forma estereoisomérica o tautomérica del compuesto de la fórmula I y/o mezclas de estas formas en cualquier proporción, y/o una sal fisiológicamente compatible del compuesto de la fórmula I, en la que Q1 es un átomo de hidrógeno, -alquilo (C1-C6), - cicloalquilo (C3-C6), -OH, -O-alquilo (C1-C6) o -O-cicloalquilo (C3-C6), donde cada uno de alquilo y cicloalquilo está sin sustituir o mono-, di- o trisustituido independientemente con -alquilo (C1-C4), -cicloalquilo (C3-C6), OH, -O-alquilo (C1-C6) o -O-cicloalquilo (C3-C6), donde algunos o todos los átomos de hidrógeno en el alquilo o cicloalquilo pueden reemplazarse por flúor, Q2 y Q3 son iguales o diferentes y cada uno es independientemente un átomo de hidrógeno, -alquilo (C1-C6) o -cicloalquilo (C3-C6), donde algunos o todos los átomos de hidrógeno en el alquilo o cicloalquilo pueden reemplazarse por flúor, R1, R2 y R3 son iguales o diferentes y cada uno es independientemente un átomo de hidrógeno, -alquilo (C1-C6), -cicloalquilo (C3-C6), -O-alquilo (C1-C8), -O-cicloalquilo (C3-C6), -alquileno (C0-C4)-C(O)-N(R11)-R12, -alquileno (C0-C4)-C(O)-O-R11, -alquileno (C0-C4)-C(O)- R11, -alquileno (C0-C4)-N(R11)-R12, -alquileno (C0-C4)-N(R11)-C(O)-R12, halógeno, OH, -CN, -NO2, -SO2CH3, -SO2CF3, -SF5, - Si[alquilo (C1-C4)]3, -alquileno (C1-C6)-O-alquilo (C1-C6), -O-alquileno (C1-C6)-O-alquilo (C1-C6), -O-alquileno (C0-C4)-arilo (C6-C14) donde el arilo está sin sustituir o mono-, di- o trisustituido independientemente con -O-alquilo (C1-C6), -alquilo (C1-C4), OH, -cicloalquilo (C3-C6) o O-cicloalquilo (C3-C6), -O-alquileno (C1-C4)-cicloalquilo (C3-C6) -Het (C4-C15) donde Het está sin sustituir o mono-, di- o trisustituido independientemente con -alquilo (C1-C4), -cicloalquilo (C3-C6), OH, -O-alquilo (C1-C6) o -O-cicloalquilo (C3-C6), o -O-alquileno (C1-C6)-O-alquileno (C1-C6)- O-alquilo (C1-C6), donde cada uno del alquilo, alquileno y cicloalquilo está sin sustituir o mono-, di-o trisustituido independientemente con-alquilo (C1-C4), - cicloalquilo (C3-C6), OH, -O-alquilo (C1-C6), -arilo (C6-C14), donde el arilo está sin sustituir o mono-, di-, tri-, tetra- o pentasustituido independientemente con halógeno, -alquilo (C1-C4), -cicloalquilo (C3-C6), ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290112 | 2008-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260083A2 true CO6260083A2 (es) | 2011-03-22 |
Family
ID=39539711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10095026A CO6260083A2 (es) | 2008-02-05 | 2010-08-04 | Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentos |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8076336B2 (es) |
| EP (1) | EP2240487B1 (es) |
| JP (1) | JP5526040B2 (es) |
| KR (1) | KR20100114514A (es) |
| CN (1) | CN101981034B (es) |
| AR (1) | AR070410A1 (es) |
| AT (1) | ATE537172T1 (es) |
| AU (1) | AU2009211887B2 (es) |
| BR (1) | BRPI0907486A2 (es) |
| CA (1) | CA2713550C (es) |
| CL (1) | CL2009000236A1 (es) |
| CO (1) | CO6260083A2 (es) |
| CY (1) | CY1113228T1 (es) |
| DK (1) | DK2240487T3 (es) |
| ES (1) | ES2379447T3 (es) |
| HK (1) | HK1149011A1 (es) |
| HR (1) | HRP20120230T1 (es) |
| IL (1) | IL207205A0 (es) |
| MA (1) | MA32061B1 (es) |
| MX (1) | MX2010008490A (es) |
| MY (1) | MY152040A (es) |
| NZ (1) | NZ587141A (es) |
| PA (1) | PA8814801A1 (es) |
| PE (1) | PE20091455A1 (es) |
| PL (1) | PL2240487T3 (es) |
| PT (1) | PT2240487E (es) |
| RS (1) | RS52264B (es) |
| RU (1) | RU2499797C2 (es) |
| SI (1) | SI2240487T1 (es) |
| TW (1) | TW200946532A (es) |
| WO (1) | WO2009097970A1 (es) |
| ZA (1) | ZA201004467B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009002842A (es) * | 2006-09-18 | 2009-05-27 | Vertex Pharma | Inhibidores heterociclicos de c-met y usos de los mismos. |
| PL2240486T3 (pl) * | 2008-02-05 | 2016-02-29 | Sanofi Sa | Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek |
| US8673890B2 (en) | 2009-10-29 | 2014-03-18 | Janssen Pharmaceutica Nv | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist |
| WO2020254554A1 (en) * | 2019-06-19 | 2020-12-24 | Nmd Pharma A/S | Process for the preparation of clc-1 chloride channel inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4578464A (en) | 1983-11-22 | 1986-03-25 | Merrell Dow Pharmaceuticals Inc. | 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds |
| WO1996008496A1 (en) * | 1994-09-16 | 1996-03-21 | Takeda Chemical Industries, Ltd. | Triazolopyridazines process and intermediates for their preparation and their use as medicaments |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| US7488742B2 (en) | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| JP4220249B2 (ja) | 2001-04-19 | 2009-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | サイクリックアミジン誘導体 |
| EP1391452A4 (en) | 2001-05-25 | 2005-10-26 | Mochida Pharm Co Ltd | 4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT |
| WO2003031442A1 (fr) | 2001-10-05 | 2003-04-17 | Takeda Chemical Industries, Ltd. | Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation |
| PE20030808A1 (es) | 2001-10-18 | 2003-09-22 | Schering Corp | Derivados triciclicos heterociclicos como antagonistas receptores de trombina |
| ATE455774T1 (de) | 2002-04-16 | 2010-02-15 | Schering Corp | Trizyklische thrombinrezeptorantagonisten |
| WO2004078721A1 (ja) | 2003-02-19 | 2004-09-16 | Eisai Co., Ltd. | 環状ベンズアミジン誘導体の製造方法 |
| TW200531688A (en) | 2004-03-05 | 2005-10-01 | Hoffmann La Roche | Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents |
| EP1813282A4 (en) | 2004-11-09 | 2011-03-02 | Eisai R&D Man Co Ltd | MEANS FOR THE TREATMENT OF ANGIOSPASM IN SUBARACHO-OAL BLOODING WITH THROMBIN RECEPTOR ANTAGONIST AS AN ACTIVE AGENT |
| NZ568807A (en) * | 2005-12-21 | 2011-05-27 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| DE102006025318A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung |
| DE102006036023A1 (de) * | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
| CA2713554C (en) | 2008-02-05 | 2016-09-06 | Sanofi-Aventis | Imidazopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| SI2242740T1 (sl) | 2008-02-05 | 2013-03-29 | Sanofi | SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila |
| PL2240486T3 (pl) * | 2008-02-05 | 2016-02-29 | Sanofi Sa | Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek |
| WO2009126624A1 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
| WO2009126861A2 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as dgat1 inhibitors |
-
2009
- 2009-01-23 MY MYPI20103226 patent/MY152040A/en unknown
- 2009-01-23 MX MX2010008490A patent/MX2010008490A/es active IP Right Grant
- 2009-01-23 JP JP2010545378A patent/JP5526040B2/ja not_active Expired - Fee Related
- 2009-01-23 CA CA2713550A patent/CA2713550C/en not_active Expired - Fee Related
- 2009-01-23 AU AU2009211887A patent/AU2009211887B2/en not_active Ceased
- 2009-01-23 WO PCT/EP2009/000406 patent/WO2009097970A1/de active Application Filing
- 2009-01-23 RS RS20120103A patent/RS52264B/en unknown
- 2009-01-23 EP EP09708289A patent/EP2240487B1/de active Active
- 2009-01-23 RU RU2010136957/04A patent/RU2499797C2/ru not_active IP Right Cessation
- 2009-01-23 CN CN2009801115086A patent/CN101981034B/zh not_active Expired - Fee Related
- 2009-01-23 SI SI200930192T patent/SI2240487T1/sl unknown
- 2009-01-23 BR BRPI0907486-4A patent/BRPI0907486A2/pt not_active IP Right Cessation
- 2009-01-23 ES ES09708289T patent/ES2379447T3/es active Active
- 2009-01-23 NZ NZ587141A patent/NZ587141A/en not_active IP Right Cessation
- 2009-01-23 PT PT09708289T patent/PT2240487E/pt unknown
- 2009-01-23 AT AT09708289T patent/ATE537172T1/de active
- 2009-01-23 DK DK09708289.5T patent/DK2240487T3/da active
- 2009-01-23 PL PL09708289T patent/PL2240487T3/pl unknown
- 2009-01-23 KR KR1020107017452A patent/KR20100114514A/ko not_active Application Discontinuation
- 2009-02-03 AR ARP090100348A patent/AR070410A1/es not_active Application Discontinuation
- 2009-02-03 TW TW098103334A patent/TW200946532A/zh unknown
- 2009-02-03 PA PA20098814801A patent/PA8814801A1/es unknown
- 2009-02-03 CL CL2009000236A patent/CL2009000236A1/es unknown
- 2009-02-03 PE PE2009000154A patent/PE20091455A1/es not_active Application Discontinuation
-
2010
- 2010-06-24 ZA ZA2010/04467A patent/ZA201004467B/en unknown
- 2010-07-25 IL IL207205A patent/IL207205A0/en unknown
- 2010-08-04 MA MA33059A patent/MA32061B1/fr unknown
- 2010-08-04 CO CO10095026A patent/CO6260083A2/es active IP Right Grant
- 2010-08-05 US US12/851,189 patent/US8076336B2/en not_active Expired - Fee Related
-
2011
- 2011-03-30 HK HK11103239.2A patent/HK1149011A1/xx not_active IP Right Cessation
- 2011-09-23 US US13/243,118 patent/US9079906B2/en not_active Expired - Fee Related
-
2012
- 2012-03-13 HR HR20120230T patent/HRP20120230T1/hr unknown
- 2012-03-14 CY CY20121100256T patent/CY1113228T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015003538A (es) | Derivados de 3-fenilisoxazolina con accion herbicida. | |
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| DK3699181T3 (da) | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat | |
| PE20200387A1 (es) | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer | |
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| HK1220121A1 (zh) | 取代的 -二氫咪唑並 喹唑啉治療淋巴瘤的用途 | |
| PE20150666A1 (es) | Inhibidores de serina/treonina cinasa | |
| CR9398S (es) | Contenedor | |
| CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| SG11201600821SA (en) | Waste incinerator ash as aerating agent for the manufacture of lightweight construction materials | |
| CO6592042A2 (es) | Derivados de n3-sustituido -n1-sulfonil-5-fluorpirimidinona | |
| TR201900662T4 (tr) | Cb2 reseptör antagonistleri olarak triazolo[4,5-d]pirimidin türevleri. | |
| SI3004107T1 (sl) | Spojine 6,7-dihidropirazolo(1,5-A)pirazin-4(5H)-ona in njihova uporaba kot negativni alosterični modulatorji receptorjev MGLUR2 | |
| AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
| GT200700098S (es) | Envase | |
| CR20150254A (es) | Compuestos quimicos | |
| WO2008111239A1 (ja) | 帯電防止剤およびその用途 | |
| CO6260083A2 (es) | Triazolopiridinas como inhibidores del par1 su produccion y su uso como medicamentos | |
| GT200700100S (es) | Envase | |
| PE20170683A1 (es) | Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2 | |
| MX2015014081A (es) | Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor de canabinoides 2 (cb2). | |
| CR20160198A (es) | Derivados de etinilo-imidazolidín-2, 4-diona como moduladore mglur4 | |
| PE20151669A1 (es) | Compuestos de azetidiniloxifenilpirrolidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |